mTOR inhibition in breast cancer: unraveling the complex mechanisms of mTOR signal transduction and its clinical implications in therapy

By O'Regan Ruth   Hawk Natalyn Nicole  

Expert Opinion on Therapeutic Targets, Vol. 15, Iss. 7, 2011-07 ,pp. : 859-872

Informa Healthcare

Access to resources Recommend Favorite

mTOR: A Novel Therapeutic Target for Diseases of Multiple Systems

By  

Current Drug Targets, Vol. 16, Iss. 10, 2015-09 ,pp. : 1107-1132

Bentham Science Publishers

Access to resources Recommend Favorite

Overcoming resistance to mTOR inhibition for enhanced strategies in clinical trials

By Naing Aung  

Expert Opinion on Investigational Drugs, Vol. 22, Iss. 6, 2013-09 ,pp. : 679-685

Informa Healthcare

Access to resources Recommend Favorite

Preclinical evaluation of the PI3K-mTOR dual inhibitor PF-04691502 as a novel therapeutic drug in nasopharyngeal carcinoma

By Wong Chi   Loong Herbert   Hui Connie   Lau Cecilia   Hui Edwin   Ma Brigette   Chan Anthony  

Investigational New Drugs, Vol. 31, Iss. 6, 2013-12 ,pp. : 1399-1408

Springer Publishing Company

Access to resources Recommend Favorite

Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignancies

By Deenen Maarten  

Investigational New Drugs, Vol. 30, Iss. 4, 2012-08 ,pp. : 1557-1565

Springer Publishing Company

Access to resources Recommend Favorite